Latest Trials Latest NewsFAQ

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

Completed

Conditions: Migraine

Interventions: Other: Aimovig

First Posted Date: 2022-01-04

Last Posted Date: 2022-01-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1839

Registration Number: NCT05177406

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: PHE885

First Posted Date: 2021-12-29

Last Posted Date: 2024-11-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 146

Registration Number: NCT05172596

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Conditions: Chronic Spontaneous Urticaria

First Posted Date: 2021-12-28

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05170724

CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

Phase 1

Withdrawn

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: IMJ995 single agent

First Posted Date: 2021-12-23

Last Posted Date: 2022-12-21

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05168748

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Ribociclib
Drug: Letrozole
Drug: Anastrozole
Drug: Goserelin
Drug: Tamoxifen
Drug: Fulvestrant

First Posted Date: 2021-12-17

Last Posted Date: 2024-10-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT05161195

Locations: 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States

and more 14 locations

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: siremadlin
Drug: venetoclax
Drug: azacitidine

First Posted Date: 2021-12-14

Last Posted Date: 2024-07-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT05155709

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸
Oregon Health Sciences University ., Portland, Oregon, United States
🇺🇸
Texas Oncology Sammons Cancer Center Sammons Cancer Center (SC), Dallas, Texas, United States

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab

First Posted Date: 2021-12-14

Last Posted Date: 2021-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16246

Registration Number: NCT05157087

Locations: 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Phase 3

Recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Remibrutinib
Drug: Teriflunomide

First Posted Date: 2021-12-14

Last Posted Date: 2024-06-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 800

Registration Number: NCT05156281

Locations: 🇺🇸
Mayo Clinic Jacksonville ., Jacksonville, Florida, United States
🇺🇸
Ctr for Neurology and Spine, Phoenix, Arizona, United States
🇺🇸
Vladimir Royter MD APMC, Hanford, California, United States

and more 52 locations

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis

Active, not recruiting

Conditions: Non-radiographic Axial Spondyloarthritis
Moderate to Severe Plaque Psoriasis
Ankylosing Spondylitis
Psoriatic Arthritis

Interventions: Other: secukinumab

First Posted Date: 2021-12-13

Last Posted Date: 2024-03-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT05155098

Locations: 🇹🇭
Novartis Investigative Site, Nakhon Ratchasima, Thailand

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib
Drug: Ribociclib
Drug: Abemaciclib

First Posted Date: 2021-12-10

Last Posted Date: 2021-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4320

Registration Number: NCT05153135

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy